Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.3 (
topoisomerase
)
9,911
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Autophagy is a lysosomal bulk degradation process for intracellular protein and organelles.
FIP200
(200 kDa FAK-family interacting protein) is an essential component of mammalian autophagy that is implicated in breast cancer in recent studies. Here we show that inactivation of
FIP200
resulted in deficient repair of DNA damage induced by ionizing radiation and anticancer agents in mouse embryonic fibroblasts (MEF). The persistent DNA damage correlated to increased apoptosis and reduced survival of
FIP200
knockout (KO) MEFs after treatments with camptothecin (CPT), a topoisomerase I inhibitor and chemotherapeutic agent. Reexpression of
FIP200
in
FIP200
KO MEFs restored both efficient DNA damage repair and cell survival. Furthermore, knockdown of the increased p62 expression in
FIP200
KO MEFs rescued the impaired DNA damage repair and CPT-induced cell death. In contrast, treatment of cells with N-acetyl cysteine did not affect these defects in
FIP200
KO MEFs. Finally,
FIP200
KO MEFs also showed deficient DNA damage repair and increased cell death compared with control MEFs, when treated with etoposide, a
topoisomerase
II inhibitor and another anticancer agent. Together, these results identify a new function for
FIP200
in the regulation of DNA damage response and cell survival through its activity in autophagy and suggest the possibility of
FIP200
or other autophagy proteins as a potential target for treatment to enhance the efficiency of cancer therapy using DNA damage-inducing agents.
...
PMID:Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents. 2180 66
